Inhibitors of Endoplasmic Reticulum -Glucosidases Potently Suppress Hepatitis C Virus Virion Assembly and Release

Drexel Institute for Biotechnology and Virology Research, Department of Microbiology and Immunology, Drexel University College of Medicine, Doylestown, PA 18902, USA.
Antimicrobial Agents and Chemotherapy (Impact Factor: 4.48). 12/2010; 55(3):1036-44. DOI: 10.1128/AAC.01319-10
Source: PubMed


α-Glucosidases I and II are endoplasmic reticulum-resident enzymes that are essential for N-linked glycan processing and subsequent proper folding of glycoproteins. In this report, we first demonstrate that downregulation of the expression of α-glucosidase I, II, or both in Huh7.5 cells by small hairpin RNA technology inhibited the production of hepatitis C virus (HCV). In agreement with the essential role of α-glucosidases in HCV envelope glycoprotein processing and folding, treatment of HCV-infected cells with a panel of imino sugar derivatives, which are competitive inhibitors of α-glucosidases, did not affect intracellular HCV RNA replication and nonstructural protein expression but resulted in the inhibition of glycan processing and subsequent degradation of HCV E2 glycoprotein. As a consequence, HCV virion assembly and secretion were inhibited. In searching for imino sugars with better antiviral activity, we found that a novel imino sugar, PBDNJ0804, had a superior ability to inhibit HCV virion assembly and secretion. In summary, we demonstrated that glucosidases are important host factor-based antiviral targets for HCV infection. The low likelihood of drug-resistant virus emergence and potent antiviral efficacy of the novel glucosidase inhibitor hold promise for its development as a therapeutic agent for the treatment of chronic hepatitis C.


Available from: Wenquan Yu
  • Source
    • "Since the human cells have a bypassing strategy for glucosidase trimming via the endomannosidase enzyme activity, it is feasible to conceive the potential low cytotoxicity of these drugs on the host cells. Celgosivir [150], PBDNJ0804-a deoxynojirimycin derivative [149], and CM-10-18 [147] are rER glucosidase I inhibitors that could show anti-C. albicans activity. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Protein glycosylation pathways are present in all kingdoms of life and are metabolic pathways found in all the life kingdoms. Despite sharing commonalities in their synthesis, glycans attached to glycoproteins have species-specific structures generated by the presence of different sets of enzymes and acceptor substrates in each organism. In this review, we present a comparative analysis of the main glycosylation pathways shared by humans and the fungal pathogen Candida albicans: N-linked glycosylation, O-linked mannosylation and glycosylphosphatidylinositol-anchorage. The knowledge of similarities and divergences between these metabolic pathways could help find new pharmacological targets for C. albicans infection.
    International Journal of Microbiology 07/2014; 2014(2):267497. DOI:10.1155/2014/267497
  • Source
    • "TLR3-expressing HEK293 (293TLR3HA, Invivogen)-derived stable reporter cell line that expresses firefly luciferase under the control of a human IFN-b promoter (293TLR3/IFNbLuc) was established and cultured as described previously (Guo et al., 2012). Dengue virus (DENV, serotype 2, New Guinea C), yellow fever virus (YFV, strain 17D), encephalomyocarditis virus (EMCV), Tacaribe virus (TCRV, strain TRVL-11,573) and HCV (genotype 2a, JC1 strain) were described previously (Chang et al., 2011, 2009, 2013b; Jiang et al., 2010; Qu et al., 2011; Zhou et al., 2011). Sendai virus (SenV, strain 52) was purchased from ATCC. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Virus infection of host cells is sensed by innate pattern recognition receptors (PRRs) and induces production of type I interferons (IFNs) and other inflammatory cytokines. These cytokines orchestrate the elimination of the viruses but are occasionally detrimental to the hosts. The outcomes and pathogenesis of viral infection are largely determined by the specific interaction between the viruses and their host cells. Therefore, compounds that either inhibit viral infection or modulate virus-induced cytokine response should be considered as candidates for managing virus infection. The aim of the study was to identify compounds in both categories, using a single cell-based assay. Our screening platform is a HEK293 cell-based reporter assay where the expression of a firefly luciferase is under the control of a human IFN-β promoter. We have demonstrated that infection of the reporter cell line with a panel of RNA viruses activated the reporter gene expression that correlates quantitatively with the levels of virus replication and progeny virus production, and could be inhibited in a dose-dependent manner by known antiviral compound or inhibitors of PRR signal transduction pathways. Using Dengue virus as an example, a pilot screening of a small molecule library consisting of 26,900 compounds proved the concept that the IFN-β promoter reporter assay can serve as a convenient high throughput screening platform for simultaneous discovery of antiviral and innate immune response modulating compounds. A representative antiviral compound from the pilot screening, 1-(6-ethoxybenzo[d]thiazol-2-yl)-3-(3-methoxyphenyl) urea, was demonstrated to specifically inhibit several viruses belonging to the family of flaviviridae.
    Antiviral research 04/2014; 107(1). DOI:10.1016/j.antiviral.2014.04.010 · 3.94 Impact Factor
  • Source
    • "For example, viruses such as the hepadnaviruses, flaviviruses, filoviruses and influenza virus are significantly repressed by imino sugars under conditions where there is no detectable affect upon the host cells, or in the cases of animal experiments, only limited affect upon the host animals36,74,84 (Table 2). The sensitivity of these viruses to glucosidase inhibitors is presumably because they possess envelope proteins that must oligomerize, and they have an apparent requirement for glucosidase processing of their glycoproteins presumably to enable time-sensitive proper calnexin mediated folding for their oligomerization.35,49,52,58,85 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Ebola virus and Marburg virus are members of the family of Filoviridae and are etiological agents of a deadly hemorrhagic fever disease. The clinical symptoms of Ebola and Marburg hemorrhagic fevers are difficult to distinguish and there are currently no specific antiviral therapies against either of the viruses. Therefore, a drug that is safe and effective against both would be an enormous breakthrough. We and others have shown that the folding of the glycoproteins of many enveloped viruses, including the filoviruses, is far more dependent upon the calnexin pathway of protein folding than are most host glycoproteins. Drugs that inhibit this pathway would be expected to be selectively antiviral. Indeed, as we summarize in this review, imino sugars that are competitive inhibitors of the host endoplasmic reticular α-glucosidases I and II, which are enzymes that process N-glycan on nascent glycoproteins and thereby inhibit calnexin binding to the nascent glycoproteins, have been shown to have antiviral activity against a number of enveloped viruses including filoviruses. In this review, we describe the state of development of imino sugars for use against the filoviruses, and provide an explanation for the basis of their antiviral activity as well as limitations.
    Emerging Microbes and Infections 11/2013; 2(11). DOI:10.1038/emi.2013.77 · 2.26 Impact Factor
Show more